Great research. It bolsters the proposition that Anavex maybe "The Last Company Standing" in the ALZ Space.
As you say all but Acadia's Pimavanserin seem to be reiterations/modifications of previously failed approaches.
Acadia's Pimavanserin is not competitive with Anaxex 2-73 as it is being tested for the very narrow indication of Dementia related psychosis.
Acadia's market cap is indicative of what Anavex market cap potential is, however. As ACAD got a huge boost in market cap because of Pimavanserin potential in the narrow indication of Parkinson's related dementia.
The disparity of Market Caps between ACAD ($2.8 Bil. and as high as $5 Bil.) and AVXL ($122 Mil) is staggering, 23X. What would a similar valuation of Anaxex do to the price of AVXL stock? One does not have to have a great imagination to see what Anavex should be valued at today. Just examine the market caps of other CNS clinical stage companies like ACAD and Sage ($7 Bil with NO APPROVALS) or like AXON ($2.4 Bil, before) in its, Wall Street sponsored pre-clinical pump stage. Why is AVXL stock priced so low? That is the $63(thousand) question and may be partly due to Anavex not being a Wall Street Sponsored/Controlled company having not IPO'd with the controlling stock interests in the hands of Wall Street. Is Wall Street getting their shares by running over and running out retail holders as best they can with manipulation?
Any chances of Anavex succeeding on anything are not yet priced into the stock. There is RISK in Anavex but the risk/reward equation is monumentally in favor of long investors like one may never see again.
It seems paradoxical yet if Anavex were to narrow its focus in ALZ to related symptoms of ALZ like insomnia and mood disorders Anavex might get a huge boost in Market Cap as Investors would see these as easier to get approval for. They could then continue with clinical trials to tackle the actual genesis of dementia in Alzheimer's.
Market Data 
Markets 
AI
